Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. Read full Trend Edge analysis →
| Current Price | $25.02 |
|---|---|
| Market Cap | $2.49B |
| Float | 304K |
| Shares Outstanding | 90.0M |
| Dividend Rate | None |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2025 | N/A | -$66.1M | N/A | N/A |
| Quarter | Revenue | Net Income |
|---|---|---|
| Mar 2025 | N/A | -$99,000 |
| Jun 2025 | N/A | -$381,000 |
| Mar 2026 | N/A | -$14.3M |
| Jun 2026 | N/A | -$15.0M |
| Insider Ownership | 58.2% |
|---|---|
| Institutional Ownership | 19.1% |
| Short Float | 459.2% |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $0.00 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $0.00 | Medium-term trend |
| Weekly | 80-Week SMA | $0.00 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $0.00 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $0.00 | Near-term monthly trend |
| Monthly | 20-Month SMA | $0.00 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $0.00 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Volume shelf data not available.
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | -0.95% | -0.95% | 0.00% | -0.95% | -0.95% |
| 1 Day | -1.70% | -1.70% | 0.00% | -1.70% | -1.70% |
| 1 Week | -6.66% | -6.66% | 0.00% | -6.66% | -6.66% |
| 2 Weeks | N/A | N/A | N/A | N/A | N/A |
| 1 Month | N/A | N/A | N/A | N/A | N/A |
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
Institutional holder breakdown coming soon.
Total institutional ownership: 19.1%
Total insider ownership: 58.2%
| Total Filings | 10 |
|---|---|
| Net Value | +$2.0M |
| Net Shares Change | 53,355,822 |
| % of Float | 17537.4% |
| C-Suite Filings | 3 |
| Clusters Detected | 1 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Forbion Growth Opportunities Fund III Cooperatief U.A. | +$64.8M | 1 | 2 buy | |
| ORBIMED ADVISORS LLC | +$34.9M | 1 | 1 buy | |
| Chimovits Erez | +$34.9M | 1 | 1 buy | |
| AH Bio Fund IV, L.P. | +$19.8M | 1 | 1 buy | |
| Murdoch Travis | CEO and President | +$1.5M | 1 | 1 buy |
| Viehbacher Christopher | +$1.5M | 1 | 1 buy | |
| Lubner David Charles | +$999,990 | 1 | 1 buy | |
| Rickey James Paul | Chief Financial Officer | +$499,986 | 1 | 1 buy |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2026-08-07 – 2026-08-11 | 10 | 10 | +$159M | 3 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-08-07 | Forbion Growth Opportunities Fund III Cooperatief U.A. | +$64.8M | Transaction at $18.00, now +39.0% | |
| 2026-08-07 | Rickey James Paul | Chief Financial Officer | +$499,986 | Transaction at $18.00, now +39.0% |
| 2026-08-07 | Murdoch Travis | CEO and President | +$1.5M | Transaction at $18.00, now +39.0% |
| 2026-08-07 | Anderson Michele A. | Chief Development Officer | +$19,998 | Transaction at $18.00, now +39.0% |
| 2026-08-11 | ORBIMED ADVISORS LLC | +$34.9M | Transaction at $18.00, now +39.0% | |
| 2026-08-11 | Chimovits Erez | +$34.9M | Transaction at $18.00, now +39.0% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Braveheart Bio, Inc. Common Stock (BRVE) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for BRVE on Trend Edge →